PT - JOURNAL ARTICLE AU - Alessandro Di Marzo AU - Michelina Casale AU - Fabio Trippa AU - Paola Anselmo AU - Fabio Arcidiacono AU - Lorena Draghini AU - Sara Terenzi AU - Ernesto Maranzano TI - Stereotactic Body Radiotherapy in Contralateral Kidney Oligometastasis From Renal Cell Carcinoma in a Nephrectomized Patient AID - 10.31486/toj.20.0080 DP - 2021 Sep 21 TA - Ochsner Journal PG - 296--300 VI - 21 IP - 3 4099 - http://www.ochsnerjournal.org/content/21/3/296.short 4100 - http://www.ochsnerjournal.org/content/21/3/296.full SO - Ochsner J2021 Sep 21; 21 AB - Background: Renal cell carcinoma (RCC) frequently metastasizes to distal organs such as the lungs, abdomen, bones, and brain. Although rare cases of adrenal gland metastasis from RCC have been described, to our knowledge, no cases have reported the use of stereotactic body radiotherapy (SBRT) in contralateral kidney oligometastasis in a nephrectomized patient with RCC.Case Report: We report a rare case of single contralateral renal metastasis from RCC in a 65-year-old female that occurred 1 year after right radical nephrectomy. At diagnosis of relapse, the patient received targeted therapy with sunitinib for 9 consecutive months, resulting in a partial regression of renal metastasis. To preserve the organ and consolidate response, SBRT was administered to the residual mass. Targeted therapy was temporarily discontinued 15 days before and after SBRT. Total SBRT dose was 40 Gy in 5 daily fractions given with volumetric modulated arc and image-guided technique. Three months later, magnetic resonance imaging documented a complete regression of disease, a result that persisted at the last follow-up 19 months after SBRT.Conclusion: The combination of sequential targeted therapy and SBRT provided an excellent outcome in a patient with a solitary kidney who experienced contralateral kidney metastasis from RCC. This treatment approach was well tolerated and controlled the disease.